Alnylam Pharmaceuticals | ALNY - Debt


Alnylam Pharmaceuticals reported $1.28B in Debt for its fiscal quarter ending in December of 2025.





Debt Change Date
Acadia Pharmaceuticals USD 52.19M 2.62M Dec/2025
Agios Pharmaceuticals USD 40.21M 4.31M Dec/2025
Alnylam Pharmaceuticals USD 1.28B 30.06M Dec/2025
Amgen USD 54.6B 17M Dec/2025
Arrowhead Research USD 312.77M 53.52M Dec/2025
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
Incyte USD 39.43M 982K Mar/2026
Ionis Pharmaceuticals USD 2.34B 9.5M Mar/2026
Moderna USD 1.31B 571M Dec/2025
Neurocrine Biosciences USD 406.2M 9.1M Mar/2026
Novartis USD 32.02B 615M Sep/2025
PTC Therapeutics USD 286.94M 2.42B Mar/2026
Regeneron Pharmaceuticals USD 2.71B 300K Mar/2026
Sangamo BioSciences USD 0 0 Jun/2022
Sanofi EUR 21.76B 530M Sep/2025
Sarepta Therapeutics USD 1.04B 210.44M Dec/2025
Takeda JPY 4.85T 208B Dec/2025
Tectonic Therapeutic USD 876K 115K Dec/2024
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
Vertex Pharmaceuticals USD 1.99B 44M Mar/2026
Xencor USD 187.75M 118.48M Dec/2025